Alnylam Pharmaceuticals (ALNY) Gross Profit (QoQ) (2018 - 2026)

Alnylam Pharmaceuticals (ALNY) Gross Profit (QoQ) (2018 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,861.65 Bn 66,861.36 Bn -
2 Nanobiotix 1,910.87 Bn 1,910.81 Bn -
3 Akari Therapeutics 989.71 Bn 989.71 Bn -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.90 Bn 61.14 Bn 3.31 Bn
7 Belite Bio 62.74 Bn 62.74 Bn -
8 Argenx Se 55.83 Bn 50.65 Bn 1.41 Bn
9 Revolution Medicines 37.46 Bn 37.46 Bn -
10 Alnylam Pharmaceuticals 37.37 Bn 34.36 Bn 959.66 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 15.72%
Dec 31, 2025 -21.15%
Sep 30, 2025 66.51%
Jun 30, 2025 20.54%
Mar 31, 2025 6.83%
Dec 31, 2024 17.09%
Sep 30, 2024 -29.30%
Jun 30, 2024 34.76%
Mar 31, 2024 19.57%
Dec 31, 2023 -45.20%
Sep 30, 2023 175.68%
Jun 30, 2023 -12.39%
Mar 31, 2023 -3.81%
Dec 31, 2022 26.81%
Sep 30, 2022 19.40%
Jun 30, 2022 0.52%
Mar 31, 2022 -15.61%
Dec 31, 2021 40.97%
Sep 30, 2021 -16.16%
Jun 30, 2021 23.14%